Australia - English - Department of Health (Therapeutic Goods Administration)

red dot rescue - commiphora myrrha, quantity: 300 microlitre/ml (equivalent: commiphora myrrha, qty 60 mg/ml); echinacea purpurea, quantity: 162 microlitre/ml (equivalent: echinacea purpurea, qty 81 mg/ml); calendula officinalis, quantity: 135 microlitre/ml (equivalent: calendula officinalis, qty 135 mg/ml); echinacea angustifolia, quantity: 108 microlitre/ml (equivalent: echinacea angustifolia, qty 54 mg/ml) - liquid, multipurpose - excipient ingredients: purified water; ethanol - traditionally used in western herbal medicine to decrease/reduce/relieve mouth/oral mucosa mild inflammation ; traditionally used in western herbal medicine to decrease/reduce/relieve symptoms of mild mouth ulcers (linked indication:helps reduce occurrence of mouth ulcers); traditionally used in western herbal medicine to astringent/tightens tissues ; traditionally used in western herbal medicine to maintain/support immune system health ; traditionally used in western herbal medicine to helps enhance/improve/promote immune system function ; traditionally used in western herbal medicine to decrease/reduce/relieve symptoms of common colds and flu (linked indication:helps decrease/reduce/relieve the severity of symptoms of common colds and flu); traditionally used in western herbal medicine to decrease/reduce/relieve symptoms of head cold ; traditionally used in western herbal medicine to decrease/reduce/relieve the severity of symptoms of mild upper respiratory tract infections (linked indication:relieve symptoms of mild upper respiratory tract infections; helps reduce occurrence of symptoms of upper respiratory tract infections); traditionally used in western herbal medicine to decrease/reduce/relieve the severity of common cold symptoms (linked indication:helps reduce occurrence of common colds; decrease/reduce/relieve common cold duration); traditionally used in western herbal medicine to decrease/reduce/relieve mild throat inflammation ; traditionally used in western herbal medicine to relieve symptoms of sore throat/pharyngitis (linked indication:helps decrease/reduce occurrence of sore throat); traditionally used in western herbal medicine to decrease/reduce/relieve symptoms of mild tonsillitis (linked indication:reduce duration of symptoms of mild tonsillitis); traditionally used in western herbal medicine to reduce scar tissue ; traditionally used in western herbal medicine to helps decrease/reduce/relieve symptoms of minor skin wounds (cuts, scratches and abrasions) (linked indication:vulnerary/wound healing; cleanse minor skin wound/cuts/scratches/abrasions; enhance/improve healing of minor skin wound/cuts/scratches/abrasions); traditionally used in western herbal medicine to helps healing of mild skin burn/sunburns

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - prednisolone sodium phosphate, quantity: 6.72 mg (equivalent: prednisolone, qty 5 mg) - suppository, moulded - excipient ingredients: hard fat - indications as at 01 jan 1991 : predsol suppositories are indicated for the treatment of haemorrhagic and granular proctitis, post-radiation proctitis and rectal complication of crohn's disease.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

nufarm australia limited - imidacloprid - suspension concentrates for seed treatment (fs) - imidacloprid guanidine active 600.0 g/l - insecticide - brassica forage crop | canola | cereal crop | clover pasture | cotton | lupin | maize | pasture seed and forage crops | sorghum - aphid | barley yellow dwarf virus | black field earwig | black sunflower scarab | blue oat or pea mite | brown flea beetle | corn aphid | eastern false wireworm | field cricket | redlegged earth mite | southern false wireworm | striate false wireworm | sugarcane wireworm - agrypnus variabilis | thrip | wheat aphid | wingless cockroach | wireworm | calolampra elegans | calolampra solida | cosmozosteria spp. | false wireworm | large false wireworm | oat aphid | red legged earth mite | telegryllus commodus | thrips spp.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

fine agrochemicals limited - benzyladenine; gibberellin a4 and gibberellin a7 - liquid - benzyladenine nucleotide active 19.0 g/l; gibberellin a4 and gibberellin a7 plant growth regulator active 19.0 g/l - plant regulator - apple - pink lady | braeburn - apple | cherry | gala apple | golden delicious apple | red delicious apple | royal gala - fruit thinning | improve fruit shape | reduce weather induced russet | stimulating plant growth | fruit thinning | stimulation of lateral growth

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - amlodipine besilate, quantity: 6.94 mg (equivalent: amlodipine, qty 5 mg); valsartan, quantity: 160 mg; hydrochlorothiazide, quantity: 12.5 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; crospovidone; magnesium stearate; titanium dioxide; hypromellose; purified talc; macrogol 4000 - exforge hct is indicated only as substitution therapy for the treatment of hypertension in patients whose blood pressure is already adequately controlled on the triple combination of amlodipine, valsartan and hydrochlorothiazide taken either as three single component formulations or as dual-component formulation with a single component formulation, all components at the same dose level. treatment should not be initiated with these fixed-dose combinations (see dosage and administration).

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - methylphenidate hydrochloride, quantity: 20 mg - capsule, hard - excipient ingredients: potassium hydroxide; iron oxide red; gelatin; povidone; shellac; purified talc; methacrylic acid copolymer; titanium dioxide; propylene glycol; ammonio methacrylate copolymer; strong ammonia solution; triethyl citrate; sucrose; maize starch - rubifen la modified release capsules are indicated for the treatment of attention-deficit hyperactivity disorder (adhd).,adhd adhd was previously known as attention-deficit disorder. other terms used to describe this behavioural syndrome include: minimal brain dysfunction in children, hyperkinetic child syndrome, minimal brain damage, minimal cerebral dysfunction, minor cerebral dysfunction and psycho-organic syndrome of children.,rubifen la modified release capsules are indicated as an integral part of a total treatment program for adhd that may include other measures (psychological, educational and social) for patients with this syndrome. stimulants are not intended for use in the patient who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis.,special diagnostic considerations for adhd in children the aetiology of this syndrome is unknown and there is no single diagnostic test. adequate diagnosis requires the use, not only of medical, but also of psychological, educational and social resources. characteristics commonly reported include: chronic history of short attention span, distractibility, emotional lability, impulsivity, moderate to severe hyperactivity, minor neurological signs and an abnormal eeg. learning may or may not be impaired. the diagnosis must be based upon a complete history and evaluation of the child and not solely on the presence of one or more of these characteristics.,drug treatment is not indicated for all children with this syndrome. stimulants are not intended for use in children who exhibit symptoms secondary to environmental factors (e.g. child abuse in particular) or primary psychiatric disorders. appropriate educational placement is essential and psychosocial intervention is generally necessary. when remedial measures alone are insufficient, the decision to prescribe stimulant medicine will depend upon the physician's assessment of the chronicity and severity of the child's symptoms.,continuation of treatment in adolescent and special diagnostic considerations for adhd in adults there is limited information to guide clinicians about how long older adolescents should continue to receive treatment with drugs for attention deficit hyperactivity disorder (adhd). the decision should be based on the extent to which symptoms of adhd and social functioning have improved to a point that medication is no longer needed. if older adolescents have been largely symptom-free for a year and are functioning well, a trial without medication is warranted. this should be undertaken at times of low stress such as during holidays or in a period when a school routine is well established.,adhd needs to be considered in adults who present with longstanding symptoms suggestive of adhd (inattention, impulsivity, disorganisation) that appear to have started in childhood and are persisting into adult life. further, people with personality disorder and/or problems with drug use accompanied by a significant level of impulsivity and inattention should be referred for evaluation by a psychiatrist with the training and skills required to assess and treat adhd. this expertise is necessary due to the overlap of adhd symptoms with anxiety, mood and personality disorders.

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - methylphenidate hydrochloride, quantity: 40 mg - capsule, hard - excipient ingredients: gelatin; strong ammonia solution; purified talc; potassium hydroxide; triethyl citrate; ammonio methacrylate copolymer; iron oxide red; propylene glycol; methacrylic acid copolymer; iron oxide yellow; titanium dioxide; povidone; shellac; sucrose; maize starch - rubifen la modified release capsules are indicated for the treatment of attention-deficit hyperactivity disorder (adhd).,adhd adhd was previously known as attention-deficit disorder. other terms used to describe this behavioural syndrome include: minimal brain dysfunction in children, hyperkinetic child syndrome, minimal brain damage, minimal cerebral dysfunction, minor cerebral dysfunction and psycho-organic syndrome of children.,rubifen la modified release capsules are indicated as an integral part of a total treatment program for adhd that may include other measures (psychological, educational and social) for patients with this syndrome. stimulants are not intended for use in the patient who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis.,special diagnostic considerations for adhd in children the aetiology of this syndrome is unknown and there is no single diagnostic test. adequate diagnosis requires the use, not only of medical, but also of psychological, educational and social resources. characteristics commonly reported include: chronic history of short attention span, distractibility, emotional lability, impulsivity, moderate to severe hyperactivity, minor neurological signs and an abnormal eeg. learning may or may not be impaired. the diagnosis must be based upon a complete history and evaluation of the child and not solely on the presence of one or more of these characteristics.,drug treatment is not indicated for all children with this syndrome. stimulants are not intended for use in children who exhibit symptoms secondary to environmental factors (e.g. child abuse in particular) or primary psychiatric disorders. appropriate educational placement is essential and psychosocial intervention is generally necessary. when remedial measures alone are insufficient, the decision to prescribe stimulant medicine will depend upon the physician's assessment of the chronicity and severity of the child's symptoms.,continuation of treatment in adolescent and special diagnostic considerations for adhd in adults there is limited information to guide clinicians about how long older adolescents should continue to receive treatment with drugs for attention deficit hyperactivity disorder (adhd). the decision should be based on the extent to which symptoms of adhd and social functioning have improved to a point that medication is no longer needed. if older adolescents have been largely symptom-free for a year and are functioning well, a trial without medication is warranted. this should be undertaken at times of low stress such as during holidays or in a period when a school routine is well established.,adhd needs to be considered in adults who present with longstanding symptoms suggestive of adhd (inattention, impulsivity, disorganisation) that appear to have started in childhood and are persisting into adult life. further, people with personality disorder and/or problems with drug use accompanied by a significant level of impulsivity and inattention should be referred for evaluation by a psychiatrist with the training and skills required to assess and treat adhd. this expertise is necessary due to the overlap of adhd symptoms with anxiety, mood and personality disorders.

Australia - English - Department of Health (Therapeutic Goods Administration)

sibutramine hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - morphine sulfate pentahydrate, quantity: 20 mg - tablet, film coated - excipient ingredients: povidone; lactose; magnesium stearate; purified talc; pregelatinised maize starch; titanium dioxide; sunset yellow fcf aluminium lake; polyvinyl alcohol; macrogol 3350; erythrosine aluminium lake - treatment of chronic severe pain of cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - morphine sulfate pentahydrate, quantity: 10 mg - tablet, film coated - excipient ingredients: lactose; povidone; pregelatinised maize starch; magnesium stearate; purified talc; titanium dioxide; brilliant blue fcf; hypromellose; macrogol 400 - treatment of chronic severe pain of cancer.